Drug Profile
EBI 215
Alternative Names: EBI-215Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Eternity Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Fusion oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Non-small cell lung cancer
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in China (PO)
- 10 Mar 2016 Phase-I development is ongoing in China
- 11 Nov 2013 EBI 215 is available for licensing worldwide (excluding China) as of 11 Nov 2013. http://www.eternitybioscience.com/